Zelira Therapeutics – Leading global therapeutic medicinal cannabis company

Zelira Therapeutics brings deep
pharmaceutical expertise to the
development and commercialisation of our
proprietary cannabinoid-based medicines.

Zelira Therapeutics…with our focus on specific
conditions, we are ‘reimagining healthcare’
for millions of people underserved by
current treatments.

We are committed to building patient and
doctor confidence in our medicines with
an ethical, evidence-based approach,
applying world-class science and
conducting clinical trials.

Zelira Therapeutics - Global Leader in cannabinoid-based medicine

Zelira Therapeutics Ltd is a leading global cannabinoid-based biopharmaceutical company with access to the world’s largest and fastest growing markets. Zelira owns a portfolio of proprietary revenue generating products and a pipeline of candidates undergoing clinical development that are positioned to enter global markets. The Company is focused on developing branded cannabinoid-based medicines for the treatment of a variety of medical conditions in its Rx business, including insomnia, autism and chronic non-cancer pain.

Recent Video and Audio from Zelira Therapeutics

Zelira Chairman Presentation at Cantor Fitzgerald International Cannabis Forum

November 17, 2022

Zelira AGM Presentation 2022

Zelira Therapeutics Chairman Osagie Imasogie and Global CEO Oludare Odumosu present a company update at the 2022 Annual General Meeting.

November 15, 2022

Zelira CEO Oludare Odumosu speaks with Proactive

Zelira Global CEO Oludare Odumosu provides Proactive with an update on the company’s progress with its proprietary revenue-generating products, global expansion and its pipeline of candidates undergoing clinical development.

September 7, 2022

Zelira Therapeutics Investor Presentation – Sept 2022

Hear the latest business updates from Zelira Therapeutics Chairman Osagie Imasogie and Global CEO Dr Oludare Odumosu.

May 12, 2022

Zelira Therapeutics Investor Presentation

Zelira Therapeutics Chairman Osagie Imasogie and Global CEO Dr Oludare Odumosu deliver a slide presentation and answer investor questions as part of a business update.

February 27, 2022

Channel 7 News Perth

Zelira product helping young patient with autism spectrum disorder

January 13, 2022

Zelira AGM Presentation January 2022

CEO Oludare Odumosu and Chairman Osagie Imasogie presentation at the Zelira AGM 2022

Zelira Therapeutics brings deep
pharmaceutical expertise to the
development and commercialisation of our
proprietary cannabinoid-based medicines.

Zelira Therapeutics…with our focus on specific
conditions, we are ‘reimagining healthcare’
for millions of people underserved by
current treatments.

We are committed to building patient and
doctor confidence in our medicines with
an ethical, evidence-based approach,
applying world-class science and
conducting clinical trials.

Zelira Therapeutics - Global Leader in cannabinoid-based medicine

Recent Video and Audio from Zelira Therapeutics

Contact Us

Follow Zelira Therapeutics

Subscribe

Zelira Therapeutics brings deep pharmaceutical expertise to the development and commercialisation of our proprietary cannabinoid-based medicines.

Zelira Therapeutics…with our focus on specific conditions, we are ‘reimagining healthcare’ for millions of people underserved by current treatments.

We are committed to building patient and doctor confidence in our medicines with an ethical, evidence-based approach, applying world-class science and conducting clinical trials.

Zelira Therapeutics - Global Leader in cannabinoid-based medicine

Recent Video and Audio from Zelira Therapeutics

Zelira Therapeutics brings deep
pharmaceutical expertise to the
development and commercialisation of our
proprietary cannabinoid-based medicines.

Zelira Therapeutics…with our focus on specific
conditions, we are ‘reimagining healthcare’
for millions of people underserved by
current treatments.

We are committed to building patient and
doctor confidence in our medicines with
an ethical, evidence-based approach,
applying world-class science and
conducting clinical trials.